Literature DB >> 24976979

Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge.

Ru Zhang1, Lingli Tu1, Lan Sun1.   

Abstract

Tyrosine kinase inhibitors (TKIs) are highly effective agents for the treatment of lung cancer which harbors activated gene mutation. However, for patients with failure of TKI, TKI re-treatment beyond progression (TRBP) is still a potential option that has been proven by many literatures. In this review, we summarize the clinical evidence of TRBP and discuss the potential mechanisms to overcome TKI-acquired resistance.

Entities:  

Keywords:  EGFR; Non-small cell lung cancer (NSCLC); acquired resistance; re-treatment; tyrosine kinase inhibitor (TKI)

Year:  2014        PMID： 24976979      PMCID： PMC4073393          DOI： 10.3978/j.issn.2072-1439.2014.04.36

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  12 in total

1.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Authors:  Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

2.  Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.

Authors:  Zhengbo Song; Xinmin Yu; Chunxiao He; Beibei Zhang; Yiping Zhang
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

3.  Clinical response to crizotinib retreatment after acquisition of drug resistance.

Authors:  Hiromichi Matsuoka; Takayasu Kurata; Isamu Okamoto; Hiroyasu Kaneda; Kaoru Tanaka; Kazuhiko Nakagawa
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

4.  Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.

Authors:  Kenichi Nishie; Tomoya Kawaguchi; Akihiro Tamiya; Tomoyasu Mimori; Naoko Takeuchi; Yoshinobu Matsuda; Naoki Omachi; Kazuhiro Asami; Kyoichi Okishio; Shinji Atagi; Tomohisa Okuma; Akihito Kubo; Yoshihito Maruyama; Shinzoh Kudoh; Minoru Takada
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

5.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

6.  Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

Authors:  Jin-Ji Yang; Hua-Jun Chen; Hong-Hong Yan; Xu-Chao Zhang; Qing Zhou; Jian Su; Zhen Wang; Chong-Rui Xu; Yi-Sheng Huang; Bin-Chao Wang; Xue-Ning Yang; Wen-Zhao Zhong; Qiang Nie; Ri-Qiang Liao; Ben-Yuan Jiang; Song Dong; Yi-Long Wu
Journal:  Lung Cancer       Date:  2012-10-15       Impact factor: 5.705

7.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

8.  Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.

Authors:  Satoshi Watanabe; Junta Tanaka; Takeshi Ota; Rie Kondo; Hiroshi Tanaka; Hiroshi Kagamu; Kosuke Ichikawa; Jun Koshio; Junko Baba; Takao Miyabayashi; Ichiei Narita; Hirohisa Yoshizawa
Journal:  BMC Cancer       Date:  2011-01-01       Impact factor: 4.430

9.  Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?

Authors:  Young Hak Kim; Akiko Fukuhara; Michiaki Mishima
Journal:  Case Rep Oncol       Date:  2011-09-20

10.  First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

Authors:  Siow Ming Lee; Iftekhar Khan; Sunil Upadhyay; Conrad Lewanski; Stephen Falk; Geraldine Skailes; Ernie Marshall; Penella J Woll; Matthew Hatton; Rohit Lal; Richard Jones; Elizabeth Toy; David Chao; Gary Middleton; Sue Bulley; Yenting Ngai; Robin Rudd; Allan Hackshaw; Chris Boshoff
Journal:  Lancet Oncol       Date:  2012-10-16       Impact factor: 41.316
View more
  1 in total

1.  Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations.

Authors:  Xuhong Jiang; Xiaoqing Li; Lingli Tu; Jin Cai; Man Wei; Zhongjun Wu; Lan Sun
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.